BOEHRINGER-INGELHEIM
9.5.2023 14:36:33 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartstream Smart Agents Delivers 70% Reduction in Back-Office Investigation Time, Proving the Case for Autonomous Operations26.3.2026 10:30:00 CET | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that Smart Agents - its agentic AI solution for bank back-office operations is delivering measurable, transformational impact, with pilot results showing a 70% reduction in investigation time per user, per break. As the industry accelerates toward a service as software (SaS) operating model, and allowing more work to get done from software solutions, Smartstream is embracing this approach with agentic AI. The results validate a fundamental shift in how financial institutions approach exception management. In one benchmark scenario, the manual processing of 500 exceptions, typically requiring 116 hours of team effort, was reduced to just a few hours under fully autonomous operations. This eliminates swivel-chair workflows and frees up teams to focus on risk oversight, decision making, and higher-value activities. Institutions continue to struggle with back-office w
Infobip Supports Thousands of Startups and Scaleups Through Startup Tribe Programme26.3.2026 10:00:00 CET | Press release
In the first five years of the programme, Infobip has provided significant value in products and services to members, helping them build and scale customer communications worldwide Global AI-first cloud communications platform Infobip, which is celebrating its 20th anniversary this year, has supported thousands of startups and scaleups from over 120 countries in the first five years of its Startup Tribe Programme. Infobip launched its Startup Tribe Programme in May 2021 to help mission-driven startups and scaleups to build and manage their customer communications and engagement strategy and grow their business. It does this by providing access up to $60,000 in credits for Infobip’s services and its global network of advisors, investors, and accelerators. In the first five year, Infobip has provided millions in the value of products and services to its programme members. By eliminating the need to build a global communications infrastructure from the ground up, Infobip’s programme enabl
LTM Positioned as a Leader in ISG’s Provider Lens™ Evaluation for Oracle Cloud and Technology Ecosystem 202526.3.2026 09:58:00 CET | Press release
Recognition highlights LTM’s leadership across key quadrants in the United States and Europe LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in multiple quadrants in the ISG Provider Lens™ Oracle Cloud and Technology Ecosystem 2025 reports for both the United States and Europe by Information Services Group (ISG), a leading global technology research and advisory firm. The ISG Provider Lens™ study evaluates leading Oracle ecosystem service providers across critical capability areas, including: Professional Services Managed Services OCI Solutions and Capabilities LTM’s positioning as a Leader across key quadrants in both regions reflects its strong Oracle ecosystem expertise, AI-led transformation approach, and proven track record in delivering large-scale enterprise cloud modernization programs. In its 2025 study, ISG highlights that the Oracle ecosystem is undergoing a fundamental shift toward AI-native architectures, multicloud-
Bureau Veritas Strengthens Global Sustainable Finance Capabilities with Expanded Climate Bonds Approved Verifier Status26.3.2026 08:30:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), is pleased to announce the expansion of its geographical scope as an Approved Verifier under the Climate Bonds Standard and Certification Scheme. Additional offices in China, Japan, India, and France are now formally listed in the Climate Bonds Verifiers Directory. This expansion builds on Bureau Veritas’ established role since the approval of its Brazilian office in 2020, further enhancing its ability to support issuers with high-quality, independent verification services across key markets. “Our expanded presence as an Approved Verifier under the Climate Bonds Standard reinforces Bureau Veritas’ commitment to advancing credible, high‑integrity sustainable finance”, said Marc Roussel, Executive Vice President, Urbanization and Assurance at Bureau Veritas. “With verifier capabilities available across key markets, we continue to deliver local expertise with global assurance standards; boosting mark
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification26.3.2026 06:13:00 CET | Press release
IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). Commercial availability of the IVDR-certified assay is anticipated by early April 2026. The IVDR replaces the former In Vitro Diagnostics Directive (IVDD), introducing significantly more stringent requirements for clinical evidence, performance evaluation, traceability, and post-market surveillance. Under IVDR, in vitro diagnostic devices are classified according to risk from Class A (lowest risk) to Class D (highest risk). Class C devices, such as IdentiClone Dx IGH, are considered high-risk tests that play a critical role in disease diagnosis an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom